Form 8-K - Current report:
SEC Accession No. 0001193125-25-236064
Filing Date
2025-10-09
Accepted
2025-10-09 17:17:19
Documents
13
Period of Report
2025-10-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d63266d8k.htm   iXBRL 8-K 53577
2 EX-10.1 d63266dex101.htm EX-10.1 124554
  Complete submission text file 0001193125-25-236064.txt   332912

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mnkd-20251007.xsd EX-101.SCH 2864
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mnkd-20251007_lab.xml EX-101.LAB 17234
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mnkd-20251007_pre.xml EX-101.PRE 10821
16 EXTRACTED XBRL INSTANCE DOCUMENT d63266d8k_htm.xml XML 3521
Mailing Address 1 CASPER STREET DANBURY CT 06810
Business Address 1 CASPER STREET DANBURY CT 06810 818-661-5000
MANNKIND CORP (Filer) CIK: 0000899460 (see all company filings)

EIN.: 133607736 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50865 | Film No.: 251385860
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)